Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biondvax Pharma ADR (NQ: BVXV )

1.820 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biondvax Pharma ADR

< Previous 1 2 3 4 Next >
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Provides Business Update, Reports FY2022 Financial Results
Via Investor Brand Network
New Evidence Proves Link Between Glandular Fever Virus and MS
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Looking to Complement Core Focus with CDMO Offering
Via Investor Brand Network
African Researchers Collaborate to Gather Data on Infectious Illnesses
Via Investor Brand Network
Exposures COVID-19
Biden Signs Measure to End National COVID-19 Emergency
Via Investor Brand Network
Topics Government
Exposures COVID-19 Political
Eczema or Asthma Predisposes Individuals to Osteoarthritis
Via Investor Brand Network
New Approach Could Boost Current Asthma Medication Efficacy
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Q1 2023 Financial Results, Business Update
Via Investor Brand Network
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Study Finds 10% of People in UK Have Autoimmune Disorders
Via Investor Brand Network
Researchers ID Antivirals That Can Fight New Infectious Illnesses
Via Investor Brand Network
Exposures COVID-19
Study Shows that Skin Conditions May Indicate Presence of Rheumatic Disease
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aims to Complement its NanoAb Core Focus with Comprehensive Contract Development 2and Manufacturing Organization Services
Via Investor Brand Network
Study Finds That Different Subtypes of Epilepsy Trigger Different Autoimmune Conditions
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Team
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
Via Investor Brand Network
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Discusses Positive Results from In Vivo Proof-of-Concept Study of Its Anti-COVID-19 NanoAb Therapy and Additional Pipeline Plans at BIO-Europe Spring
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapies
Via Investor Brand Network
Exposures COVID-19
Scientists Sound Alarm on Climate-Change-Induced Rise of Deadly infections
Via Investor Brand Network
Topics Climate Change
Exposures Climate
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants
Via Investor Brand Network
Exposures COVID-19
Japan to Categorize COVID-19 as Common Infectious Illness
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring
Via Investor Brand Network
Exposures COVID-19
BiondVax to Present at BIO-Europe Spring
From BiondVax Pharmaceuticals Ltd.
Via GlobeNewswire
Study Shows Air Pollution in Urban Areas Worsens Lung Function in Kids
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders
Via Investor Brand Network
IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.